WallStreetZenWallStreetZen

NASDAQ: BCLI
Brainstorm Cell Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their BCLI stock forecasts and price targets.

Forecast return on equity

Is BCLI forecast to generate an efficient return?

Insufficient data to display

Forecast return on assets

Is BCLI forecast to generate an efficient return on assets?

Company
N/A
Industry
23.59%

BCLI earnings per share forecast

What is BCLI's earnings per share in the next 2 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$1.60
Avg 2 year Forecast
-$1.33

BCLI vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
BCLI$1.09N/AN/A
APLM$6.43N/AN/A
XTLB$1.31N/AN/A
TRAW$1.43N/AN/A
INDP$0.47$5.00+963.83%Strong Buy
View Top Biotech Stocks

Brainstorm Cell Therapeutics Stock Forecast FAQ

What is BCLI's earnings growth forecast for 2025-2026?

(NASDAQ: BCLI) Brainstorm Cell Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.35%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 22.38%.

Brainstorm Cell Therapeutics's earnings in 2025 is -$11,623,000.On average, 1 Wall Street analyst forecast BCLI's earnings for 2025 to be -$10,435,760, with the lowest BCLI earnings forecast at -$10,435,760, and the highest BCLI earnings forecast at -$10,435,760.

In 2026, BCLI is forecast to generate -$8,674,726 in earnings, with the lowest earnings forecast at -$8,674,726 and the highest earnings forecast at -$8,674,726.

If you're new to stock investing, here's how to buy Brainstorm Cell Therapeutics stock.

What is BCLI's forecast return on equity (ROE) for 2025-2027?

(NASDAQ: BCLI) forecast ROE is N/A, which is considered weak.

What is BCLI's Earnings Per Share (EPS) forecast for 2025-2026?

(NASDAQ: BCLI) Brainstorm Cell Therapeutics's current Earnings Per Share (EPS) is -$2.31. On average, analysts forecast that BCLI's EPS will be -$1.60 for 2025, with the lowest EPS forecast at -$1.60, and the highest EPS forecast at -$1.60. In 2026, BCLI's EPS is forecast to hit -$1.33 (min: -$1.33, max: -$1.33).

What is BCLI's forecast return on assets (ROA) for 2025-2027?

(NASDAQ: BCLI) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 23.59%.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.